Brokerages forecast that Theravance Biopharma Inc (NASDAQ:TBPH) will report $12.32 million in sales for the current fiscal quarter, according to Zacks. Three analysts have made estimates for Theravance Biopharma’s earnings, with the highest sales estimate coming in at $13.96 million and the lowest estimate coming in at $10.40 million. Theravance Biopharma posted sales of $4.52 million in the same quarter last year, which would indicate a positive year over year growth rate of 172.6%. The business is expected to issue its next earnings results on Tuesday, February 26th.
On average, analysts expect that Theravance Biopharma will report full year sales of $57.86 million for the current fiscal year, with estimates ranging from $55.00 million to $60.00 million. For the next year, analysts forecast that the business will report sales of $75.73 million, with estimates ranging from $56.30 million to $100.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that cover Theravance Biopharma.
Theravance Biopharma (NASDAQ:TBPH) last posted its earnings results on Tuesday, November 6th. The biopharmaceutical company reported ($1.10) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.18) by $0.08. The firm had revenue of $12.84 million for the quarter, compared to the consensus estimate of $10.55 million. Theravance Biopharma had a negative net margin of 513.41% and a negative return on equity of 505.90%.
A number of hedge funds have recently added to or reduced their stakes in TBPH. FNY Investment Advisers LLC bought a new stake in Theravance Biopharma during the fourth quarter valued at about $42,000. Quantamental Technologies LLC bought a new stake in Theravance Biopharma during the fourth quarter valued at about $102,000. United Services Automobile Association bought a new stake in Theravance Biopharma during the third quarter valued at about $210,000. Xact Kapitalforvaltning AB bought a new stake in Theravance Biopharma during the third quarter valued at about $285,000. Finally, Man Group plc bought a new stake in Theravance Biopharma during the third quarter valued at about $292,000. Institutional investors own 83.94% of the company’s stock.
Theravance Biopharma stock traded up $1.07 during mid-day trading on Friday, hitting $27.12. 118,998 shares of the company’s stock were exchanged, compared to its average volume of 157,139. The company has a debt-to-equity ratio of 6.52, a current ratio of 3.26 and a quick ratio of 3.08. The company has a market capitalization of $1.50 billion, a price-to-earnings ratio of -4.98 and a beta of 1.75. Theravance Biopharma has a 1-year low of $21.27 and a 1-year high of $35.48.
Theravance Biopharma Company Profile
Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to staphylococcus aureus and other gram-positive bacteria.
Read More: What are retained earnings?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.